We collaborate with leading scientific institutions around the world to tackle
Broad adoption of organoids in pharmaceutical R&D and clinical practise requires a paradigm shift across the entire value chain, including academia, industry, clinicians, regulators, and payers. This is why we aim to bring together all these stakeholders to advance translational research and personalised medicine. Our interdisciplinary research teams are uniquely positioned to unlock organoids’ transformative potential for drug discovery, development, and patient care. To bridge academic and pharmaceutical research and develop the next generation of organoids, we have organised the institute in two areas, underpinned by various teams:
- We tackle long-term R&D programmes with close links to academic groups, focusing on molecular organoid technologies, central nervous system modelling, and precision medicine.
- We develop cutting-edge technology platforms, leveraging the latest advances in microtechnologies, organoid engineering, and organoid phenotyping.